Study Reveals Practice Gap for Patients Undergoing Endometrial Biopsy
The trajectory of follow-up care for women undergoing a failed endometrial biopsy has been largely unexplored.
Gynecologic, Ovarian, and Cervical Cancer News
GYNECOLOGIC CANCER ADVISOR
TP53 Mutations Present in HPV-Negative Vulvar Cancer
In a whole-exome analysis, the most common mutations occurred in TP53, and mutations in other known cancer-associated genes were identified in women with HPV-negative vulvar cancer.
Uterus-Preserving Surgery May Be an Option for Ovarian Cancer Subtype
Women with Stage I primary mucinous epithelial ovarian carcinoma who underwent uterus-preserving surgery did not have worse survival, a retrospective study found.
Neoadjuvant Chemotherapy Increases Immunogenicity of High-Grade Serous Ovarian Cancer
This study sought to address outstanding questions regarding tumor heterogeneity in the setting of HGSOC, including its relationship with treatment response.
Birth Rates After ART Not Significantly Different Among Female Cancer Survivors, Siblings
The researchers found that patients who received pelvic radiation had a decreased chance of live birth.
KEYNOTE-100: Pembrolizumab Had Modest Activity in Recurrent Advanced Ovarian Cancer
Analysis of biomarkers to predict response to pembrolizumab are ongoing.
Olaparib/Cediranib Combination Is Not Superior to Standard of Care in Recurrent Ovarian Cancer
Overall survival data are not currently mature. However, at the time of this analysis no difference in overall survival was observed between the 3 treatment arms.
Secondary Cytoreductive Surgery Extended PFS in Recurrent Ovarian Cancer
A longer treatment-free survival interval associated with surgery may contribute to overall survival.
Tyrer-Cuzick Breast Cancer Model Well-Calibrated Among Most Races/Ethnicities
The TC model uses various parameters to predict risk such as genetic risk and nonfamilial factors including personal, hormonal, and lifestyle characteristics.
CA-125 as a Biomarker of Response to Immune Checkpoint Therapy in Ovarian Cancer
Although ICI therapy has been shown to have limited efficacy in ovarian cancer (OC), some patients with OC do achieve long-term clinical benefit from this approach.
Adverse Event Comparison in Patients With Cervical and Endometrial Cancer After IRMT or Standard Radiotherapy
Clinicians may be underappreciating the extent of adverse events in women with cervical and endometrial cancer who undergo radiotherapy.
Later Bedtime May Be Associated With Higher Levels of Pain in Ovarian Cancer Survivors
An analysis utilized the baseline characteristics of patients with pretreated ovarian cancer enrolled in a phase 3 trial to evaluate lifestyle interventions.
Mirvetuximab Soravtansine Plus Bevacizumab in FRα-Overexpressing Advanced Epithelial Ovarian Cancer
This study evaluated the combination of bevacizumab with an antibody drug conjugate targeted to the folate receptor alpha in the setting of epithelial ovarian cancer.
First Study To Report OS Benefit After Secondary Cytoreductive Surgery in Select Patients With Recurrent Ovarian Cancer
A key enrollment criterion in this randomized trial was a positive AGO score, a predictor of resectability in patients with recurrent ovarian cancer.
Study Supports Delaying Cervical Cancer Surgery in COVID-19 Hotspots
Delay in surgery for early-stage cervical cancer was not associated with worse short-term outcomes, supporting the suggestion to delay surgery in COVID-19 hotspots.
Maintenance Olaparib Boosted Survival by 1 Year in Relapsed BRCA-Related Ovarian Cancer
Olaparib should be new standard for maintenance in these patients.
Molecular Subtypes of Endometrial Clear Cell Carcinoma Appear to Have Prognostic Differences
Molecular subtypes, as indicated by the ProMisE classifier, of endometrial clear cell carcinoma are associated with different prognoses.
Lynparza Plus Bevacizumab Approved for First-Line Maintenance in HRD-Positive Advanced Ovarian Cancer
The FDA has approved Lynparza® for use in combination with bevacizumab as first-line maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer
Zejula Approved for Maintenance Treatment of Advanced Ovarian Cancer
Results showed a statistically significant improvement in PFS for Zejula compared with placebo, regardless of biomarker status.
Somatic Driver Mutations Leading to Endometrial Cancer Occur Early in Life
One finding of this study was that the mutational landscapes of normal endometrial glandular tissue were influenced by patient age and parity.
-
Loading...
-
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Gynecologic Cancer
